Developing drugs to reduce brain inflammation in HIV patients
Development of NLRP3 inhibitors for HIV-associated neuroinflammation
This study is looking at new ways to help people with HIV by testing a special treatment that could reduce inflammation in the brain, which might improve thinking and memory skills for those experiencing related issues.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11168648 on NIH RePORTER |
What this research studies
This research focuses on creating inhibitors for the NLRP3 inflammasome, which is linked to inflammation and neurocognitive disorders in individuals living with HIV. By targeting this inflammasome, the study aims to reduce the persistent inflammation that contributes to conditions like HIV-associated neurocognitive disorders (HAND). The approach involves testing small molecules, such as AMS-17, to see if they can effectively block NLRP3 activation and improve neurological health. Patients may benefit from new treatment options that could enhance their cognitive function and overall quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are experiencing neurocognitive disorders or related symptoms.
Not a fit: Patients who are not living with HIV or do not have neurocognitive symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that alleviate neurocognitive disorders in HIV patients, improving their cognitive health and quality of life.
How similar studies have performed: Previous research has shown promise in targeting the NLRP3 inflammasome for neuroinflammation, indicating potential for success in this approach.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Bukrinsky, Michael Ilya — George Washington University
- Study coordinator: Bukrinsky, Michael Ilya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.